Intersect Ent Inc
NASDAQ:XENT
Intersect Ent Inc
Cash from Financing Activities
Intersect Ent Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Intersect Ent Inc
NASDAQ:XENT
|
Cash from Financing Activities
$51.3m
|
CAGR 3-Years
58%
|
CAGR 5-Years
93%
|
CAGR 10-Years
N/A
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash from Financing Activities
-$2.3B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-10%
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Financing Activities
$5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
N/A
|
|
Stryker Corp
NYSE:SYK
|
Cash from Financing Activities
-$1.5B
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-25%
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Financing Activities
-$7.1B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Financing Activities
$46.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
See Also
What is Intersect Ent Inc's Cash from Financing Activities?
Cash from Financing Activities
51.3m
USD
Based on the financial report for Mar 31, 2022, Intersect Ent Inc's Cash from Financing Activities amounts to 51.3m USD.
What is Intersect Ent Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
93%
Over the last year, the Cash from Financing Activities growth was -23%. The average annual Cash from Financing Activities growth rates for Intersect Ent Inc have been 58% over the past three years , 93% over the past five years .